Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors

被引:21
|
作者
Choi, Yong Jun [1 ]
Kim, Taehee [1 ]
Kim, Eun Young [1 ]
Lee, Sang Hoon [1 ]
Kwon, Do Sun [1 ]
Chang, Yoon Soo [1 ]
机构
[1] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Hyperprogressive disease; NSCLC; PD-L1; inhibitor; prognosis; BONE-MARROW; SURVIVAL; NIVOLUMAB; DOCETAXEL; BLOCKADE;
D O I
10.1111/1759-7714.13594
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Hyperprogressive disease (HPD) is a paradoxical acceleration of tumor growth after immune checkpoint inhibitor (ICI) treatment. This study aimed to identify the risk factors and to present a predictive model for HPD in patients treated with ICIs. Methods A total of 78 non-small cell lung cancer (NSCLC) cases, treated with at least two cycles of ICIs who underwent computed tomography (CT) for response assessment were recruited into the study from January 2016 to August 2019. HPD was defined by the following criteria: (i) time-to-treatment failure <2 months; (ii) a 50% increase in the sum of target lesion diameters; (iii) new development of at least two lesions in an already involved organ; (iv) appearance of a new organ lesion; and (v) a decrease in ECOG PS 2. Results Of the 78 total patients, 15 (19.2%) had HPD. The risk factors of HPD were age; primary lesion size; and metastases in the contralateral lung, pleura, liver, and bone in multivariable logistic regression (odds ratio [OR]; 0.9038, 1.6619, 28.5913, 23.8264, 14.5711, and 20.1533, respectively, allP-values < 0.05). By using these risk factors, we developed a prediction model for HPD and the area under the receiver operating characteristic curve of the model was 0.9556 (95% confidence interval [CI]: 0.9133-0.9978). Conclusions HPD is relatively common and associated with a grave clinical outcome, requiring a careful monitoring in lung cancer patients treated with ICIs. Moreover, risk factors such as age, size of tumor and number of various metastatic lesions should be taken into consideration before ICI administration. Key pointsSignificant findings of the study Age, primary lesion size, and number of metastases are risk factors of HPD. HPD is strongly associated with poor prognosis. HPD during ICI use needs comprehensive monitoring. What this study adds This is the first study to develop a prediction model. The area under the curve of the prediction model for HPD was 0.9556.
引用
收藏
页码:2793 / 2803
页数:11
相关论文
共 50 条
  • [1] Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
    Ayala de Miguel, P.
    Lopez Gallego, J.
    Gorospe Garcia, I.
    Illan Varella, A.
    Rivera Vargas, P. R.
    Posada Restrepo, A.
    Borrega Garcia, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Hyperprogressive Disease in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Lo Russo, G.
    Signorelli, D.
    Proto, C.
    Galli, G.
    Prelaj, A.
    Ferrara, R.
    Sommariva, M.
    Moro, M.
    Cancila, V.
    Ganzinelli, M.
    Brich, S.
    Sangaletti, S.
    Pruneri, G.
    Tripodo, C.
    Colombo, M. P.
    Rivoltini, L.
    Balsari, A.
    Sozzi, G.
    Boeri, M.
    Garassino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S245 - S245
  • [3] Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
    Britt, Alec S.
    Huang, Caitlyn
    Huang, Chao H.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] The incidence and risk factors of hyperprogressive disease(HPD) in non-small cell lung cancer(NSCLC) treated with immune checkpoint inhibitors(ICI)
    Kim, Hyeonseon
    Lee, Yeun Ho
    Song, Chiwoo
    Kim, Leeseul
    Kim, Min Jeong
    Choi, Horyun
    Kim, Jinah
    Chae, Young Kwang
    CANCER RESEARCH, 2022, 82 (12)
  • [5] The incidence and predictive factors of hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI).
    Lee, Yeun Ho
    Kim, Hyeonseon
    Chung, Il-Young
    Song, Chiwoo
    Kim, Leeseul
    Choi, Horyun
    Kim, Jinah
    Oh, Youjin
    Lee, Grace Yujin
    Cho, Heayoon
    Chae, Young Kwang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer
    Lo Russo, Giuseppe
    Facchinetti, Francesco
    Tiseo, Marcello
    Garassino, Marina Chiara
    Ferrara, Roberto
    CURRENT ONCOLOGY REPORTS, 2020, 22 (05)
  • [7] Hyperprogressive disease during treatment with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC).
    Ayala de Miguel, Pablo
    Lopez Gallego, Javier
    Gorospe Garcia, Itziar
    Rivera Vargas, Pablo Rene
    Posada Restrepo, Andrea
    Aires Machado, Jonathan
    Alonso Calderon, Ruben
    Rodriguez Garcia, Jose Manuel
    Ceballos, Eduardo
    Acero Caballero, Alfonso
    Illan Varella, Andrea
    Quintana Cortes, Laura
    Borrega Garcia, Pablo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    ONKOLOGE, 2017, 23 (10): : 838 - 844
  • [9] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Herzberg, Benjamin
    Campo, Meghan J.
    Gainor, Justin F.
    ONCOLOGIST, 2017, 22 (01): : 81 - 88
  • [10] Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Xue, Chongxiang
    Dong, Huijing
    Chen, Ying
    Lu, Xingyu
    Zheng, Shuyue
    Cui, Huijuan
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (06): : 779 - 788